Granny does need a biotech, I never put ALDX in there.
Hmmmm.
Gotta dig deeper on this one.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
Hmmmm.
Gotta dig deeper on this one.
Stoney....
When people have something like this.... does insurance pay for it?!
"Treatment of hemophilia B today consists of prophylactic or on-demand protein replacement therapy, in which frequent intravenous administrations of plasma-derived or recombinant hFIX are required to stop or prevent bleeding. Protein replacement therapy is expensive, often costing up to $500,000 to $775,000 per patient per year in the United States. "
A quick look at the chart, and we are certainly bottom fishing on this one. I have to wonder if that analyst is scrambling here.
And there's this:
uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring exclusive global rights to etranacogene dezaparvovec. Under the terms of the agreement, which was completed in May 2021, uniQure receives a $450 million cash payment and will be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones. uniQure will also be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percent of on net sales of products arising from the collaboration based on sales thresholds.
Looking at the options history, over the last year several people have made some big bets and lost huge. But one has to wonder why they made those bets. Perhaps the (forthcoming) news was just late?
Interesting find Stoney.
$27 looks good for now.
When people have something like this.... does insurance pay for it?!
"Treatment of hemophilia B today consists of prophylactic or on-demand protein replacement therapy, in which frequent intravenous administrations of plasma-derived or recombinant hFIX are required to stop or prevent bleeding. Protein replacement therapy is expensive, often costing up to $500,000 to $775,000 per patient per year in the United States. "
A quick look at the chart, and we are certainly bottom fishing on this one. I have to wonder if that analyst is scrambling here.
And there's this:
uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring exclusive global rights to etranacogene dezaparvovec. Under the terms of the agreement, which was completed in May 2021, uniQure receives a $450 million cash payment and will be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones. uniQure will also be eligible to receive tiered double-digit royalties in a range of up to a low-twenties percent of on net sales of products arising from the collaboration based on sales thresholds.
Looking at the options history, over the last year several people have made some big bets and lost huge. But one has to wonder why they made those bets. Perhaps the (forthcoming) news was just late?
Interesting find Stoney.
$27 looks good for now.
Hi Van-
I have been following QURE for probably six years. I would have to say this is probably the worst management in biotech! When you want them to be aggressive and PR-like, they button up and act very European. They have had set backs but never of the kind that makes you doubt the technology. I have watched analysts over the years stick with this Co. There is a base attraction that I think holds.
I am very comfortable with you holding this stk here. It will go to the high $40's.
And yes I think l insurance does pay for Hemophilia.
The areas of interest: CRSPR tech.... AMRS<--- This is synthetic biology... I dpn't fully understand but it is perhaps the next frontier after CRSPR.... And believe it or not Mushrooms an area I do Understand!!!
COMPASS Pathways
I have been following QURE for probably six years. I would have to say this is probably the worst management in biotech! When you want them to be aggressive and PR-like, they button up and act very European. They have had set backs but never of the kind that makes you doubt the technology. I have watched analysts over the years stick with this Co. There is a base attraction that I think holds.
I am very comfortable with you holding this stk here. It will go to the high $40's.
And yes I think l insurance does pay for Hemophilia.
The areas of interest: CRSPR tech.... AMRS<--- This is synthetic biology... I dpn't fully understand but it is perhaps the next frontier after CRSPR.... And believe it or not Mushrooms an area I do Understand!!!
COMPASS Pathways
- Perhaps the largest company in terms of market cap focused exclusively on psychedelic treatments is COMPASS Pathways (CMPS+0.7%), which just had its IPO in September 2020.
- The company's lead asset is COMP360, a compound containing psilocybin, the active ingredient in "magic mushrooms." The candidate is in phase 2b for treatment-resistant depression.
- Earlier this month, Cantor Fitzgerald reiterated a buy rating on shares and $71 price target, even though the stock is down 18% over the last six months.
- Analyst Charles Duncan cited an April 2021 New England Journal of Medicine report that found psilocybin had as good or better efficacy than Lexapro (escitalopram), a commonly prescribed selective serotonin reuptake inhibitor antidepressant.
- MindMed (MNMD-2.2%) is another top psychedelics player with a large capitalization.
- The company is engaged in Project Lucy, currently in phase 2a, that uses doses of LSD to treat anxiety. This LSD microdosing is also under investigation for ADHD.
- MindMed is also partnered with University Hospital Basel to conduct R&D on LSD, MDMA (also knows as ecstasy), DMT, and psilocybin.
- Over the last six months, share are up ~5%, but are up 870% over the last one-year period.
- Backed by venture capitalist Peter Thiel, atai Life Sciences (ATAI-3.9%) just had itsIPO last month.
- Psychedelic drugsmake up five of the 10 candidates in the company's pipeline, which include MDMA, ketamine and psilocybin.
- atai acts more like a holding company of psychedlic-focused companies.
- Its most advanced psychedelic candidate is PCN-101, a racemic ketamine for treatment-resistant depression, which has completed phase 1.
- DMX-1002, a form of ibogaine, is in phase 1 for opioid use disorder.
- In the preclinical stage, it has EMP-01, an MDMA derivative for PTSD, and VLS-01, a form of DMT for treatment-resistant depression.
- Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgeraldrecently initiated atai with buy/overweight ratings.
- atai priced its June IPO at $15 per share. On Friday, shares closed $17.38 (~16% upside since IPO).
- Although not a pure play psychedelic therapy company, one of Seelos Therapeutics' (SEEL-1.2%) lead candidates is SLS-002, an intranasal racemic ketamine for acute suicidal ideation and behavior in patients with major depression.
- SLS-002 is also under investigation for PTSD.
- Earlier this month, Seelos started dosing in the second partof a randomized, double-blind, placebo-controlled proof-of-concept study.
- Top-line data from part one of the study released in May was positive.
- At that time, BTIG initiated shares with a buy rating and $14 price target, while B. Riley reiterated its buy rating and $15 price target.
- More recently, Seelos was initiated with a buy at Guggenheim Securities with an $8 price target.
- Seelos shares are up over 54% year-to-date.
Back to QURE. That agreement with CSL Behring-- It came when the company was thought to be in play. So there was this large sell off as a take over seemed off the table.
Then they had a clinical hold put on them stock sold=ff again... Now that hold is lifted and this agreement is finalized, etc. The stk has not rebounded. A very big opportunity for Van (and GBA)
SIGNED- THE BOTTOM HUNTER
Then they had a clinical hold put on them stock sold=ff again... Now that hold is lifted and this agreement is finalized, etc. The stk has not rebounded. A very big opportunity for Van (and GBA)
SIGNED- THE BOTTOM HUNTER
I don't often give guarantees because I cannot control these outcomes. But I guarantee you $50 and maybe $60 out of this name.
June 22->
PsyBio initiates European manufacturing of proprietary biosynthetic psychedelic compounds
Jun. 22, 2021 7:50 AM ET PsyBio Therapeutics Corp. (PSYBF)PsyBio Therapeutics Corp. (PSYBF)
Today- PSYBF
- PsyBio Therapeutics(OTCPK
SYBF)has initiated its first, European pilot scale batch manufacturing of its psychedelic portfolio of compounds with the proprietary biosynthetic formulation of psilocybin in collaboration with Biose Industrie.
- "Biose is the ideal partner for us in the EU with extensive expertise and capability to not only produce individual therapies in a regulatorily compliant manner, but to also facilitate the development and testing of combination therapies," Chief Medical Officer Michael Spigarelli said.
PsyBio Therapeutics uplists to OTCQB Market
Jul. 14, 2021 11:35 AM ETPsyBio Therapeutics Corp. (PSYBF)PsyBio Therapeutics Corp. (PSYBF)PsyBio Therapeutics (OTCPK
A dear friend of ours with a lot of serious trauma is going to try this psilocybin therapy. Not sure about the biosynthetic part.
I just went through the thread and dug this up-- Not on the other list of Mushroom stks.
Not Easy!!! Many pages, found this again.
BMBIF-
PSYBF-
AMRS-
BLL-
GHVI-
CUTR-
PSYBF-
AMRS-
BLL-
GHVI-
CUTR-
Last edited:
About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.